Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine

Jason Yeung; Tian Wang; Pei-Yong Shi

doi:10.1016/j.coviro.2023.101347

Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine

Curr Opin Virol. 2023 Oct:62:101347. doi: 10.1016/j.coviro.2023.101347. Epub 2023 Aug 19.

Authors

Jason Yeung¹, Tian Wang², Pei-Yong Shi³

Affiliations

¹ Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
² Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
³ Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Drug Discovery, University of Texas Medical Branch, Galveston, TX, USA; Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA; Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: peshi@utmb.edu.

PMID: 37604085
DOI: 10.1016/j.coviro.2023.101347

Abstract

The effectiveness of early COVID-19 vaccines in reducing the severity of the disease has led to a focus on developing next-generation vaccines that can prevent infection and transmission of the virus. One promising approach involves the induction of mucosal immunity through nasal administration and a variety of mucosal vaccine candidates using different platforms are currently in development. Live-attenuated viruses, less pathogenic versions of SARS-CoV-2, have promising features as a mucosal vaccine platform and have the potential to induce hybrid immunity in individuals who have already received mRNA vaccines. This review discusses the potential benefits and considerations for the use of live-attenuated SARS-CoV-2 intranasal vaccines and highlights the authors' work in developing such a vaccine platform.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
Immunity, Mucosal
SARS-CoV-2

Substances

COVID-19 Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding